CN107613968A - 预防或治疗脂肪肝的药物组合物 - Google Patents

预防或治疗脂肪肝的药物组合物 Download PDF

Info

Publication number
CN107613968A
CN107613968A CN201680021216.3A CN201680021216A CN107613968A CN 107613968 A CN107613968 A CN 107613968A CN 201680021216 A CN201680021216 A CN 201680021216A CN 107613968 A CN107613968 A CN 107613968A
Authority
CN
China
Prior art keywords
liver
mannitol
combination
acid
eriodictyol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680021216.3A
Other languages
English (en)
Chinese (zh)
Inventor
胡幼圃
何欣恬
吴永恩
唐熙卉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sinew Pharma Inc
Original Assignee
Sinew Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinew Pharma Inc filed Critical Sinew Pharma Inc
Priority to CN202310336366.5A priority Critical patent/CN116440143A/zh
Publication of CN107613968A publication Critical patent/CN107613968A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23B—PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
    • A23B2/00—Preservation of foods or foodstuffs, in general
    • A23B2/70—Preservation of foods or foodstuffs, in general by treatment with chemicals
    • A23B2/725—Preservation of foods or foodstuffs, in general by treatment with chemicals in the form of liquids or solids
    • A23B2/729—Organic compounds; Microorganisms; Enzymes
    • A23B2/733—Compounds of undetermined constitution obtained from animals or plants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Botany (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
CN201680021216.3A 2015-11-19 2016-03-31 预防或治疗脂肪肝的药物组合物 Pending CN107613968A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310336366.5A CN116440143A (zh) 2015-11-19 2016-03-31 预防或治疗脂肪肝的药物组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562257697P 2015-11-19 2015-11-19
US62/257,697 2015-11-19
PCT/CN2016/078039 WO2017084234A1 (zh) 2015-11-19 2016-03-31 预防或治疗脂肪肝的药物组合物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310336366.5A Division CN116440143A (zh) 2015-11-19 2016-03-31 预防或治疗脂肪肝的药物组合物

Publications (1)

Publication Number Publication Date
CN107613968A true CN107613968A (zh) 2018-01-19

Family

ID=58718029

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680021216.3A Pending CN107613968A (zh) 2015-11-19 2016-03-31 预防或治疗脂肪肝的药物组合物
CN202310336366.5A Pending CN116440143A (zh) 2015-11-19 2016-03-31 预防或治疗脂肪肝的药物组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310336366.5A Pending CN116440143A (zh) 2015-11-19 2016-03-31 预防或治疗脂肪肝的药物组合物

Country Status (7)

Country Link
US (1) US10925854B2 (https=)
EP (1) EP3391881A4 (https=)
JP (4) JP2018534323A (https=)
CN (2) CN107613968A (https=)
HK (1) HK1244213A1 (https=)
TW (1) TWI711464B (https=)
WO (1) WO2017084234A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110151787A (zh) * 2018-02-12 2019-08-23 玛旺干细胞医学生物科技股份有限公司 护肝组合物及其用途

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201890810A1 (ru) * 2015-09-24 2018-11-30 Синью Фарма Инк. Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение
TWI691719B (zh) * 2018-10-19 2020-04-21 香港商阿瓦隆 海帕波有限公司 半乳糖快速定量檢測系統及其應用
US20220265603A1 (en) * 2019-06-25 2022-08-25 National Hospital Organization Hepatic fibrosis-inhibiting agent and brown fat cell-activating agent containing taxifolin
CN112471376A (zh) * 2020-11-02 2021-03-12 辽宁康汇医学临床研究有限公司 一种防治酒精性脂肪肝的固体饮料及其制备方法
CN113440514B (zh) * 2021-08-20 2022-09-09 中国农业科学院郑州果树研究所 含橙皮素的组合物及其制备降血糖药物的应用
CN117205159A (zh) * 2023-09-04 2023-12-12 中国医学科学院药用植物研究所 一种自纳米组合物及制备方法与应用
CN119184297A (zh) * 2024-09-18 2024-12-27 中国农业大学 葛根素及其衍生物调控des1改善肝脏脂质堆积及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004083468A (ja) * 2002-08-26 2004-03-18 Aotsubu:Kk アブラナ科植物の抽出物とその用途
CN100540559C (zh) * 2003-04-03 2009-09-16 株式会社林原生物化学研究所 类脂化合物调节剂及其用途
CN101683351A (zh) * 2008-09-24 2010-03-31 汪鋆植 根皮苷在制备保肝药物或保健食品中的用途
CN103168907A (zh) * 2011-12-22 2013-06-26 国际香料和香精公司 清凉增强组合物
WO2015070396A1 (zh) * 2013-11-13 2015-05-21 财团法人国防教育研究基金会 无肝副作用的对乙酰胺基酚新复方组合
CN107614475A (zh) * 2015-09-24 2018-01-19 欣耀生医股份有限公司 有效于治疗肝毒性及脂肪肝疾病的化合物及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4388328A (en) * 1981-10-15 1983-06-14 Warner-Lambert Company Sorbitol containing mixture encapsulated flavor
US5080910A (en) * 1990-05-15 1992-01-14 Werner-Lambert Company Stabilized chlorodeoxysugar sweetening agents in powder form and methods for preparing same
US5804165A (en) * 1996-07-24 1998-09-08 Arnold; Michael J. Antiplaque oral composition
EP1072264A4 (en) * 1998-04-16 2004-07-28 Ajinomoto Kk MEDICINES FOR THE PRIMARY BILE CIRCLES
JP4824886B2 (ja) * 2001-09-11 2011-11-30 長岡香料株式会社 フルクトース吸収阻害剤、組成物、および食品
JPWO2006135084A1 (ja) * 2005-06-14 2009-01-08 学校法人 久留米大学 脂肪性肝炎または脂肪肝の予防または治療薬
JP2007182405A (ja) * 2006-01-10 2007-07-19 Univ Kurume 脂肪性肝疾患の改善治療薬
JPWO2009028457A1 (ja) * 2007-08-29 2010-12-02 国立大学法人信州大学 非アルコール性脂肪肝炎治療薬
CN101744865B (zh) * 2008-12-18 2012-07-25 山东福田药业有限公司 一种木糖醇护肝片的制备方法
KR20120008034A (ko) * 2009-03-17 2012-01-25 엡탈리스 파마 캐나다 아이엔씨. 우르소데옥시콜산의 증가된 투여량으로 비알콜성 지방간염을 치료하는 방법
TR200904862A1 (tr) * 2009-05-29 2010-12-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Sukraloz formülasyonu ve üretim prosesi
CN101933900A (zh) * 2009-07-02 2011-01-05 天津瑞普生物技术股份有限公司 一种用于防治禽类肝病的复方制剂及其制备方法
JP2011231078A (ja) * 2010-04-30 2011-11-17 Nagaoka Koryo Kk 非アルコール性脂肪性肝疾患の予防および／または治療に有効な経口摂取用組成物
AR083417A1 (es) 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
DE112011105169B4 (de) * 2011-04-20 2021-11-04 National Defense Education And Research Foundation Neue pharmazeutische orale Zusammensetzung mit geringen Nebenwirkungen enthaltend anti-Tuberkulose Arzneimittel
CN102908596B (zh) * 2011-08-05 2014-09-03 成都永康制药有限公司 一种治疗脂肪肝的中药组合物
US20140274979A1 (en) * 2013-03-13 2014-09-18 Golden Biotechnology Corporation Method for the treatment of fatty liver disease
US10441560B2 (en) * 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
JP6194412B2 (ja) * 2013-04-29 2017-09-06 ハーシャ チグルパティ アルコール飲料の毒性低減
CN103432528A (zh) * 2013-08-23 2013-12-11 冯庄明 一种治疗非酒精性脂肪肝的中药制剂

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004083468A (ja) * 2002-08-26 2004-03-18 Aotsubu:Kk アブラナ科植物の抽出物とその用途
CN100540559C (zh) * 2003-04-03 2009-09-16 株式会社林原生物化学研究所 类脂化合物调节剂及其用途
CN101683351A (zh) * 2008-09-24 2010-03-31 汪鋆植 根皮苷在制备保肝药物或保健食品中的用途
CN103168907A (zh) * 2011-12-22 2013-06-26 国际香料和香精公司 清凉增强组合物
WO2015070396A1 (zh) * 2013-11-13 2015-05-21 财团法人国防教育研究基金会 无肝副作用的对乙酰胺基酚新复方组合
CN107614475A (zh) * 2015-09-24 2018-01-19 欣耀生医股份有限公司 有效于治疗肝毒性及脂肪肝疾病的化合物及其用途

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
M. ASHRAFUL ALAM等: "Effect of Citrus Flavonoids, Naringin and Naringenin, on Metabolic Syndrome and Their Mechanisms of Action", 《ADV. NUTR.》 *
M. ASHRAFUL ALAM等: "Effect of Citrus Flavonoids, Naringin and Naringenin, on Metabolic Syndrome and Their Mechanisms of Action", 《ADV. NUTR.》, vol. 5, 31 December 2014 (2014-12-31), pages 404 - 417, XP093024953, DOI: 10.3945/an.113.005603 *
MASANORI HIRAMITSU等: "Eriocitrin ameliorates diet-induced hepatic steatosis with activation of mitochondrial biogenesis", 《SCIENTIFIC REPORTS》 *
MASANORI HIRAMITSU等: "Eriocitrin ameliorates diet-induced hepatic steatosis with activation of mitochondrial biogenesis", 《SCIENTIFIC REPORTS》, vol. 4, 15 January 2014 (2014-01-15), pages 1 - 11 *
TEERADATE KONGPICHITCHOKE 等: ""Number of Hydroxyl Groups on the B Ring of Flavonoids Affects Their Antioxidant Activity and Interaction with Phorbol Ester Binding Site of PKCδ C1B Domain: In Vitro and in Silico Studies"", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 63, pages 4580 - 4586 *
TEERADATE KONGPICHITCHOKE等: "Number of Hydroxyl Groups on the B Ring of Flavonoids Affects Their Antioxidant Activity and Interaction with Phorbol Ester Binding Site of PKCδ C1B Domain: In Vitro and in Silico Studies", 《JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY》 *
TEERADATE KONGPICHITCHOKE等: "Number of Hydroxyl Groups on the B Ring of Flavonoids Affects Their Antioxidant Activity and Interaction with Phorbol Ester Binding Site of PKCδ C1B Domain: In Vitro and in Silico Studies", 《JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY》, vol. 63, 24 April 2015 (2015-04-24), pages 4580 *
YOSHIAKI MIYAKE等: "Lipid-Lowering Effect of Eriocitrin, the Main Flavonoid in Lemon Fruit, in Rats on a High-Fat and High-Cholesterol Diet", 《JOURNAL OF FOOD SCIENCE》 *
YOSHIAKI MIYAKE等: "Lipid-Lowering Effect of Eriocitrin, the Main Flavonoid in Lemon Fruit, in Rats on a High-Fat and High-Cholesterol Diet", 《JOURNAL OF FOOD SCIENCE》, vol. 71, no. 9, 31 December 2006 (2006-12-31), pages 633 *
王悦之等: "CYP2E1 与非酒精性脂肪肝", 胃肠病学和肝病学杂志, vol. 21, no. 4, pages 384 - 386 *
王颢等: "柚皮素抑制高脂饮食肥胖大鼠体重的实验研究", 《中国现代医学杂志》 *
王颢等: "柚皮素抑制高脂饮食肥胖大鼠体重的实验研究", 《中国现代医学杂志》, vol. 18, no. 15, 31 August 2008 (2008-08-31), pages 2131 - 2137 *
王颢等: "柚皮素抑制高脂饮食肥胖大鼠体重的实验研究", 中国现代医学杂志, vol. 18, no. 15, pages 2131 - 2137 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110151787A (zh) * 2018-02-12 2019-08-23 玛旺干细胞医学生物科技股份有限公司 护肝组合物及其用途

Also Published As

Publication number Publication date
JP2021105037A (ja) 2021-07-26
CN116440143A (zh) 2023-07-18
HK1244213A1 (zh) 2018-08-03
EP3391881A1 (en) 2018-10-24
TW201718015A (zh) 2017-06-01
JP2023145714A (ja) 2023-10-11
JP2025124769A (ja) 2025-08-26
US20180117003A1 (en) 2018-05-03
WO2017084234A1 (zh) 2017-05-26
JP7690526B2 (ja) 2025-06-10
EP3391881A4 (en) 2020-03-11
US10925854B2 (en) 2021-02-23
JP2018534323A (ja) 2018-11-22
TWI711464B (zh) 2020-12-01

Similar Documents

Publication Publication Date Title
JP7690526B2 (ja) 脂肪肝の予防または処置用医薬組成物
Yang et al. Maresin1 protect against ferroptosis-induced liver injury through ROS inhibition and Nrf2/HO-1/GPX4 activation
Ye et al. Poria cocos polysaccharides rescue pyroptosis-driven gut vascular barrier disruption in order to alleviates non-alcoholic steatohepatitis
Li et al. Fenretinide attenuates lipopolysaccharide (LPS)-induced blood-brain barrier (BBB) and depressive-like behavior in mice by targeting Nrf-2 signaling
Zeng et al. l-Theanine attenuates liver aging by inhibiting advanced glycation end products in d-galactose-induced rats and reversing an imbalance of oxidative stress and inflammation
Yuan et al. Protective effect of resveratrol on kidney in rats with diabetic nephropathy and its effect on endoplasmic reticulum stress.
Wei et al. Di-(2-ethylhexyl) phthalate increases plasma glucose and induces lipid metabolic disorders via FoxO1 in adult mice
Shi et al. Polysaccharide from Potentilla anserina L ameliorate pulmonary edema induced by hypobaric hypoxia in rats
Zhang et al. Urolithin A, a pomegranate metabolite, protects pancreatic β cells from apoptosis by activating autophagy
Chua et al. The anti-viral and anti-inflammatory properties of edible bird’s nest in influenza and coronavirus infections: From pre-clinical to potential clinical application
Park et al. Narirutin fraction from citrus peels attenuates alcoholic liver disease in mice
Wang et al. Resveratrol inhibits MRGPRX2-mediated mast cell activation via Nrf2 pathway
Sun et al. L-theanine relieves acute alcoholic liver injury by regulating the TNF-α/NF-κB signaling pathway in C57BL/6J mice
Sun et al. Baicalin and N-acetylcysteine regulate choline metabolism via TFAM to attenuate cadmium-induced liver fibrosis
Tian et al. Selegiline ameliorated dyslipidemia and hepatic steatosis in high-fat diet mice
Wang et al. 6′-O-Caffeoylarbutin from Que Zui tea ameliorates acetaminophen-induced liver injury via enhancing antioxidant ability and regulating the PI3K signaling pathway
Zhou et al. Schisandrin B inhibits inflammation and ferroptosis in S. aureus-induced mastitis through regulating SIRT1/p53/SLC7A11 signaling pathway
Zhang et al. Tangduqing granules attenuate insulin resistance and abnormal lipid metabolism through the coordinated regulation of PPARγ and DGAT2 in type 2 diabetic rats
WO2016026139A1 (zh) 用于治疗非酒精性脂肪肝疾病的药物及应用
Sun et al. Gastroprotective effect of fucoidan from Sargassum siliquastrum against ethanol-induced gastric mucosal injury
KR101018531B1 (ko) 대잎둥굴레 또는 층층갈고리둥굴레 추출물을 유효성분으로 포함하는 비만 또는 대사 증후군 예방 및 치료용 조성물
Ma et al. Fucoxanthin ameliorates ulcerative colitis by maintaining the epithelial barrier via blocking JAK2/STAT3 signaling pathway
Sohail et al. Antifibrotic potential of reserpine (alkaloid) targeting Keap1/Nrf2; oxidative stress pathway in CCl4-induced liver fibrosis
Chen et al. Gypensapogenin I alleviates PANoptosis, ferroptosis, and oxidative stress in myocardial ischemic–reperfusion injury by targeting the NOX2/AMPK pathway
KR20150130352A (ko) 지방간 질환을 치료하는 방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1244213

Country of ref document: HK